Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Transarterial radioembolization"
Filter
Filter
Article category
Publication year
Review Articles
Radioembolization for hepatocellular carcinoma: what clinicians need to know
Jin Woo Choi, Hyo-Cheol Kim
J Liver Cancer. 2022;22(1):4-13.   Published online February 23, 2022
DOI: https://doi.org/10.17998/jlc.2022.01.16
  • 9,436 Views
  • 487 Downloads
  • 9 Citations
AbstractAbstract PDF
Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of 90Y radioactive microspheres available, namely, glass and resin microspheres, with comparable clinical outcomes. In general, TARE outperforms transarterial chemoembolization regarding post-embolization syndrome, time to progression, tumor downsizing for liver transplantation, and hospitalization stay. Although TARE is commonly recommended for patients with unresectable large HCCs, it can be an alternative to or performed in combination with ablation, surgical resection, and systemic treatment. This review aimed to address 90Y radioactive microspheres, patient selection, clinical outcomes, simulation tests, radioembolization procedures, follow-up imaging, and complications.

Citations

Citations to this article as recorded by  
  • Unlocking Precision in Radioembolization: Navigating the Future of Holmium-166 Radioembolization Mapping and Lung Shunt Study by Implementing Scout Dosimetry
    Peiman Habibollahi, Armeen Mahvash, Nima Kokabi, Nariman Nezami
    CardioVascular and Interventional Radiology.2024; 47(4): 451.     CrossRef
  • Feasibility of Liver Transplantation after 90Y Radioembolization: Lessons from a Radiation Protection Incident
    Marine Soret, Jacques-Antoine Maisonobe, Philippe Maksud, Stéphane Payen, Manon Allaire, Eric Savier, Charles Roux, Charlotte Lussey-Lepoutre, Aurélie Kas
    Health Physics.2024;[Epub]     CrossRef
  • Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management
    Cody R. Criss, Mina S. Makary
    Current Oncology.2024; 31(4): 2076.     CrossRef
  • Selective internal radiation therapy segmentectomy: A new minimally invasive curative option for primary liver malignancies?
    Riccardo Inchingolo, Francesco Cortese, Antonio Rosario Pisani, Fabrizio Acquafredda, Roberto Calbi, Riccardo Memeo, Fotis Anagnostopoulos, Stavros Spiliopoulos
    World Journal of Gastroenterology.2024; 30(18): 2379.     CrossRef
  • Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients
    Sung Won Chung, Heejin Cho, Hyunjae Shin, Jeayeon Park, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Myungsu Lee, Yoon Jun Kim, Jin Chul Paeng, Jung-Hwan Yoon, Jin Wook Chung, Jeong-Hoon Lee, Hyo-Cheol Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review
    Brandon M. Meyers, Jennifer J. Knox, David M. Liu, Deanna McLeod, Ravi Ramjeesingh, Vincent C. Tam, Howard J. Lim
    Cancer Treatment Reviews.2023; 118: 102584.     CrossRef
  • Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors
    Cody R. Criss, Mina S. Makary
    Biology.2023; 12(7): 999.     CrossRef
  • Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region
    Imam Waked, Sherif Alsammany, Sayed Hammad Tirmazy, Kakil Rasul, Jafar Bani‐Issa, Wael Abdel‐Razek, Ashraf Omar, Amr Shafik, Salem Eid, Amr Abdelaal, Ahmed Hosni, Gamal Esmat
    Liver International.2023; 43(10): 2062.     CrossRef
  • Impact of Low Skeletal Muscle Mass on Long-Term Outcomes in Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization: A Retrospective Multi-Center Study
    Heechul Nam, Hyun Yang, Ho Soo Chun, Han Ah Lee, Joon Yeul Nam, Jeong Won Jang, Yeon Seok Seo, Do Young Kim, Yoon Jun Kim, Si Hyun Bae
    Cancers.2023; 15(21): 5195.     CrossRef
Close layer
Transarterial Approach in Early Stage HCC: From Palliative Therapy to Curative Therapy
Jung Suk Oh, Ho Jong Chun
Journal of the Korean Liver Cancer Study Group. 2012;12(2):93-96.   Published online September 30, 2012
  • 587 Views
  • 3 Downloads
AbstractAbstract PDF
Early stage hepatocellular carcinoma (HCC) based on BCLC staging system can be curatively treated by liver transplantation, surgical resection or percutaneous ablation. However, transarterial approaches, including transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), are standard of care for intermediate stage HCC and can be an alternative treatment in the patients with early stage HCC which are unresectable, unsuitable for percutaneous ablation, or not eligible for liver transplantation. Many previous TACE studies in early stage HCC revealed that the overall survival rate was competitive with those of curative therapies considering their operation risks, but recurrence-free survival rate was significantly lower than curative therapies. Moreover, the histopathologic reports about TACE in early stage HCC demonstrated that only 38% of the HCC nodules were completely necrotic after TACE and only 81% of the nodules with complete response by EASL criteria showed complete necrosis. Although there is no long-term survival data about TARE in early stage HCC, a histopathologic report about TARE showed that 73% of the HCC nodules were completely necrotic after TARE and 100% of the nodules with complete response by EASL criteria showed complete necrosis. In conclusion, TACE is now limited to be categorized into a curative therapy in early stage HCC, according to the previous data about TACE. However, new recent technologies including C-arm CT, superselective embolization technique, drug-eluting bead (DEB) may sufficiently improve the survival data of TACE to prove its curative role. Considering its RFA-comparable histopathologic tumor response, TARE may prove to be a potential curative therapeutic for early stage HCC.
Close layer

JLC : Journal of Liver Cancer